Navigation Links
Codexis Names David Anton VP Bioindustrials R&D
Date:3/25/2008

REDWOOD CITY, Calif., March 25 /PRNewswire/ -- Codexis, Inc., today announced the appointment of David Anton, Ph.D. to the newly-created position of Vice President, Bioindustrials Research and Development. He joins Codexis from DuPont, where he was Venture Manager, Biofuels. He will report to Alan Shaw, Ph.D., President and CEO.

"Codexis targets major global energy and environmental markets where clean technology can make a significant impact," said Alan Shaw, Ph.D., President and CEO. "We are currently working with Shell in the development of biofuels, and expect to apply our technology to other potential new bioindustrial applications, such as carbon capture and storage, waste water purification and cleaner chemical manufacturing."

"Dr. Anton has over 25 years experience directing the development of new technology solutions and production processes at one of the world's largest science companies," Dr. Shaw added. "His experience as a scientist and venture manager in bioindustrials can make an important, immediate contribution to this important Codexis business. We are pleased to expand our management team with such a well known and broadly-experienced research executive."

Dr. Anton joined DuPont in 1983 and held a variety of senior research management positions across bioprocessing and biocatalysis. He led the process research, development and commercialization of several products, including 1,3 propanediol (a chemical intermediate used in a variety of industrial applications ranging from airplane deicing fluids to textiles and carpet). As Vice President, Research and Development for DuPont's joint venture with Tate and Lyle, he directed technology start-up activities for the first 100 million-pound plant for 1,3 propanediol, commissioned in Loudon, TN in 2006. As Venture Manager, Biofuels, he was global business lead for development of DuPont's advanced biofuel, biobutanol.

He holds a bachelor's degree in biochemistry from the University of California, Berkeley, and a Ph.D. in biochemistry from the University of Minnesota. He is a member of the joint DOE/USDA Biomass Research and Development Technology Advisory Committee.

Codexis, Inc., a clean technology company, is a leading developer of biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. These technologies enable novel solutions for efficient, cost-effective and environmentally-friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the U.S. EPA recognized Codexis with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information, please visit http://www.codexis.com.

Contact: Justin Jackson, jjackson@burnsmc.com, Burns McClellan, 212-213-0006, or Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
2. Rothwell, Wolf Elected to Codexis Board
3. Codexis Opens Singapore Laboratory
4. Bruce Pasternack Elected to Codexis Board
5. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
6. Codexis Appoints Singapore Laboratories Managing Director
7. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
8. Cato Research Names John Cline as President
9. Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors
10. Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
11. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
Breaking Biology News(10 mins):